Santos, Nilton José [UNESP]Barquilha, Caroline Nascimento [UNESP]Barbosa, Isabela Correa [UNESP]Macedo, Rodrigo Tavares [UNESP]Lima, Flávio Oliveira [UNESP]Justulin, Luis Antônio [UNESP]Barbosa, Guilherme OliveiraCarvalho, Hernandes F.Felisbino, Sérgio Luis [UNESP]2022-05-012022-05-012021-08-12International journal of molecular sciences, v. 22, n. 16, 2021.1422-0067http://hdl.handle.net/11449/233548Prostate cancer (PCa) is the leading cause of cancer-associated mortality in men, and new biomarkers are still needed. The expression pattern and protein tissue localization of proteoglycans of the syndecan family (SDC 1-4) and syntenin-1 (SDCBP) were determined in normal and prostatic tumor tissue from two genetically engineered mouse models and human prostate tumors. Studies were validated using SDC 1-4 and SDCBP mRNA levels and patient survival data from The Cancer Genome Atlas and CamCAP databases. RNAseq showed increased expression of Sdc1 in Pb-Cre4/Ptenf/f mouse Pca and upregulation of Sdc3 expression and downregulation of Sdc2 and Sdc4 when compared to the normal prostatic tissue in Pb-Cre4/Trp53f/f-;Rb1f/f mouse tumors. These changes were confirmed by immunohistochemistry. In human PCa, SDC 1-4 and SDCBP immunostaining showed variable localization. Furthermore, Kaplan-Meier analysis showed that patients expressing SDC3 had shorter prostate-specific survival than those without SDC3 expression (log-rank test, p = 0.0047). Analysis of the MSKCC-derived expression showed that SDC1 and SDC3 overexpression is predictive of decreased biochemical recurrence-free survival (p = 0.0099 and p = 0.045, respectively), and SDC4 overexpression is predictive of increased biochemical recurrence-free survival (p = 0.035). SDC4 overexpression was associated with a better prognosis, while SDC1 and SDC3 were associated with more aggressive tumors and a worse prognosis.enggene expressionoutcomeprognostic markerprostate cancersurvivalsyndecanArtigo10.3390/ijms221686692-s2.0-85115042413